Quick Links
Eli Lilly's GLP-1 Sales Nearly Double — LLY CFD Leverage Scenarios & Sector Impact
Data Snapshot
Key Takeaways
- •LLY full-year 2025 revenue hit $65.2B (+45% YoY), with Mounjaro and Zepbound combining for $36.5B — both drugs grew over 110% YoY in Q4.
- •Leverage risk: A 50x long LLY CFD entered at $907.50 faces liquidation on a ~2% drawdown to ~$889 — tight stop discipline is critical post-gap.
- •NVO is the direct cross-market loser, with US GLP-1 market share falling to 39.1% as Lilly expands to 60.5%.
- •LLY's $1T market cap milestone adds incremental bullish weight to S&P 500 and healthcare sector ETF (XLV) CFD positions.
- •2026 guidance of $80–83B implies continued structural growth, but late post-earnings entries at elevated leverage carry disproportionate liquidation risk.
Eli Lilly reported blockbuster full-year 2025 results, with total revenue reaching $65.2B — up 45% year-over-year from $45B in 2024, according to multiple industry sources including Pharmaceutical Tec
Event Summary
Eli Lilly reported blockbuster full-year 2025 results, with total revenue reaching $65.2B — up 45% year-over-year from $45B in 2024, according to multiple industry sources including Pharmaceutical Technology and Investing.com. Q4 revenue alone came in at $19.29B, beating consensus by $1.3B, with adjusted EPS of $7.54 versus $6.73 expected.
The growth engine was tirzepatide: Mounjaro (diabetes) generated $23B for the full year (+110% YoY in Q4 at $7.41B), while Zepbound (obesity) added $13.5B (+122% YoY in Q4 at $4.26B). Combined Q4 GLP-1 revenue reached $11.7B. LLY stock surged approximately 7% premarket, pushing Lilly to an estimated $1 trillion market cap — the first pharma company to reach that milestone. The company guided 2026 revenue to $80–83B. This result fits squarely within the Q1 Earnings Beat & Outlook Upgrade Wave reshaping healthcare sector positioning.
Leverage Impact Analysis
With LLY trading at $907.50 (24h range: $850.99–$919.45, +6.15%), CoinUnited's stock CFD traders with leveraged long positions are sitting on substantial gains — but late entries face elevated liquidation risk near the top of the day's range.
Worked Example — Long CFD: A trader opening a 50x long LLY CFD at $850.99 (the 24h low) with a $1,000 margin controls $50,000 notional. At the current price of $907.50, that position is up ~$3,327 — a 332% return on margin. However, with 50x leverage, a 2% pullback from $907.50 to ~$889 would erase roughly 100% of that margin.
Liquidation Risk at Current Levels: Traders entering long positions at today's open near $907–$919 with leverage above 20x face liquidation if LLY retraces to the $880–$888 zone — a realistic mean-reversion target after a single-session +6% gap. Monitor for volume exhaustion near the $919.45 resistance (24h high) as a signal of fading momentum.
Post-earnings gaps historically attract profit-taking. Traders should consider reducing leverage or tightening stops, particularly given that the earnings beat & outlook upgrade catalyst is now fully priced into the open.
Cross-Market Impact
Healthcare Sector (XLV): LLY's dominant 60.5% US GLP-1 market share directly lifts healthcare sector ETFs. The State Street Health Care Select Sector SPDR ETF holds LLY as a top weighting — outperformance here is directional.
Novo Nordisk (NVO): Novo Nordisk A/S is the clearest loser. NVO's US GLP-1 market share has declined to 39.1% (down 2.6pp QoQ), and its growth trajectory is decelerating. Expect continued pressure on NVO CFDs as the GLP-1 share gap widens.
Broad Indices: LLY's $1T market cap milestone adds weight to the S&P 500 Index and NASDAQ 100 Index. Healthcare now joins tech as a mega-cap growth driver. Index CFD longs benefit modestly from LLY's weighting contribution.
Macro/Forex: Limited direct forex impact. Volume-driven GLP-1 growth (46% volume increase, 5–7% price decline) is deflationary at the drug level, offering marginal relief to healthcare cost inflation narratives.
Trading Considerations
Key levels to watch: $919.45 (24h high / resistance), $907.50 (current price / pivot), and $880–$888 (mean-reversion support zone after the gap). A close above $919 on high volume would signal continuation toward prior all-time highs; failure to hold $890 intraday may trigger short-term momentum unwinds from leveraged longs.
The 2026 revenue guidance of $80–83B implies ~25% further top-line growth — sustaining the bull case structurally. However, traders should watch for drug pricing policy headlines and any NVO competitive pipeline updates, which remain the primary downside catalysts for the GLP-1 trade.
Trade Eli Lilly and Company on CoinUnited.io
Frequently Asked Questions
LLY surged +6.15% to $907.50 post-earnings, generating strong gains for existing long CFD holders. However, traders entering at current levels with leverage above 20x face liquidation if the stock retraces ~2% to the $888–$889 zone.
Continue Exploring
Disclaimer: This brief is for educational purposes only and is not investment advice.